Dave Humphrey Email & Phone Number

La Jolla, California, US

• Clinical-stage biotechnology company using proprietary technology platforms to develop safer prescription drugs. Developing new class of tamper-proof opioids that prevent both drug abuse and overdose.
• Led transition to a public company with Nasdaq listing through merger with a special purpose acquisition company (SPAC) in June 2021 providing cash proceeds of $8 million.
• Drive ongoing financing efforts resulting in a variety of successful transactions: - Convertible debt offerings of $15 million in Sept '21, $8 million in June '22 and $2 million in Oct '23. - Public offerings of stock.
• Guide investor relations through investor presentations, quarterly earnings calls and communications with analysts and key investors.
• Established administrative infrastructure with implementation of HR and IT systems for payroll, insurance benefits, 401k plan, stock plan administration and Microsoft 365.

• As part of core executive management team, I advised the board of directors during an extensive strategic review process resulting in a $75 million acquisition by Firmenich, a private Swiss multinational flavor and.
• I guided the company through a period of cash concerns with increased focus on forecasting, budgeting and spending which yielded expense reductions of $3.8 million or 11% compared to prior periods.

• I created program valuation models and analyzed a range of possible alternatives for the board of directors during an asset divestiture process that yielded $10 million of critical, non-dilutive funding.
• I directed investor relations efforts in conducting quarterly earnings calls, determining financial guidance, developing investor conference presentations and maintaining communications with analysts and investors.

• I prepared financial due diligence, co-developed corporate presentation and coordinated with investment bankers for public financing efforts and with an investor group for $14 million equity financing vehicle.
• I managed multiple administrative functions covering finance, accounting, cash management, stock administration, payroll and purchasing.

• I directed public company financial reporting, including Forms 10-K, 10-Q, 8-K, S-3, S-8, proxy statements and SOX internal controls compliance, acting as primary liaison with Audit Committee and external auditors.

Based on my interest in personal finance, I founded a fee-only personal financial planning firm providing integrated financial advice to individuals, families and small business owners. I analyzed client finances and designed a customized strategy based upon current financial situation, goals and risk tolerance. I monitored and adapted client financial.

• I consulted at the controller level for multiple biotechnology and medical device companies, including Senomyx, LMA North America and Akesis Pharmaceuticals.
• Projects included S-1 filing for IPO, monthly financial reporting, 10-K and annual audit preparation, Sarbanes-Oxley assessment, stock administration, income tax provisions and consolidations.

La Jolla, CA, US

• I established financial operations for a growing start-up biotechnology company, collaborating with the executive team and Board of Directors to develop the business and financing strategy.
• Managed relationships with investment bankers and venture capitalists, completing a $20 million venture capital financing round that included four new investors.
• Developed financial infrastructure, including accounting controls, policies and procedures.
• Directed accounting, purchasing, treasury, insurance and stock administration functions.

• I managed the accounting operations, including staff of eight, for a growing public company with biotechnology and instrumentation manufacturing operations.
• Provided operational forecasts, planning and analysis for company managers.
• Implemented and managed financial components of enterprise-wide Oracle Applications ERP system.
• Performed financial due diligence and integration of multiple mergers and acquisitions.
• Completed financial reporting for $71 million private equity investment and $86 million acquisition.
• Coordinated audits and prepared financial disclosures for Nasdaq initial public offering (IPO).

• I led the accounting operations for the worldwide corporate headquarters as well as the biotechnology and medical device divisions.
• Prepared and analyzed financial statements for external reporting and management review.
• Created financial models for both short-term operational forecasting and long-term strategic planning, including extensive mergers and acquisitions analysis for a $150 million international acquisition.

GB

I planned, coordinated and monitored independent audits, as well as trained, supervised and evaluated performance of staff accountants. I evaluated client accounting systems and resolved significant accounting issues.